Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.
Amos, K. D., Adamo, B., & Anders, C. K. (2012). Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials. International Journal of Breast Cancer, 2012, 1–7. https://doi.org/10.1155/2012/385978